Medica SurB de CV (MEX:MEDICAB) Research & Development: MXN0 Mil (TTM As of Dec. 2025)


MEX:MEDICAB Medica Sur SAB de CV MEX:MEDICAB
86 GF Score
Price MXN60.77
GF Value MXN47.66
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medica SurB de CV Research & Development?

Medica SurB de CV MEX:MEDICAB 86 Research & Development is MXN0 Mil as of Dec. 2025. GuruFocus rates MEX:MEDICAB with a GF Score™ of 86/100 and a GF Value™ of MXN47.66 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medica SurB de CV's Research & Development for the three months ended in Dec. 2025 was MXN0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was MXN0 Mil.

Medica SurB de CV  (MEX:MEDICAB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medica SurB de CV Research & Development Related Terms

Medica SurB de CV Research & Development Historical Data

* Premium members only.

The historical data trend for Medica SurB de CV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medica SurB de CV Research & Development Chart

Medica SurB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medica SurB de CV Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:MEDICAB
86GF Score
Medica Sur SAB de CV MEX:MEDICAB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medica SurB de CV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN0 Mil mean?
Medica SurB de CV (MEX:MEDICAB) has a Research & Development of MXN0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Medica SurB de CV and its competitors.
Is Medica SurB de CV's Research & Development too high?
Medica SurB de CV's current Research & Development is MXN0 Mil. Overall, Medica SurB de CV has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medica SurB de CV's Research & Development compare to HCA and THC?
Medica SurB de CV's Research & Development of MXN0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medica SurB de CV and its competitors. Medica SurB de CV's current Research & Development is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medica SurB de CV stock overvalued right now?
Based on GuruFocus' analysis, Medica SurB de CV (MEX:MEDICAB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN47.66, compared to a current price of MXN60.77 — trading 27.5% above its estimated fair value. The current Research & Development is MXN0 Mil. Medica SurB de CV's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medica SurB de CV (MEX:MEDICAB), the current Research & Development is MXN0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medica SurB de CV (MEX:MEDICAB) Overvalued in 2026?

Based on GuruFocus' analysis, Medica SurB de CV stock appears to be overvalued. The current stock price of MXN60.77 is trading 27.5% above its estimated GF Value™ of MXN47.66. GuruFocus considers Medica SurB de CV to be Modestly Overvalued.

Key valuation signals for MEX:MEDICAB:

  • Research & Development: MXN0 Mil
  • GF Value™: MXN47.66 vs. price of MXN60.77 (27.5% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the MEX:MEDICAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medica SurB de CV Business Description

Address Puente de Piedra 150, Col. Toriello Guerra,Tlalpan, Mexico, DF, MEX, 14050
Medica Sur SAB de CV is a medical care company specializes in emergency scenarios. The company offers emergency ambulance transportation, air transportation and paramedic assistance.
86GF Score

Get the complete analysis for MEX:MEDICAB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN60.77
Price
MXN47.66
GF Value